Caio Max Rocha Lima to Proto-Oncogene Proteins c-bcl-2
This is a "connection" page, showing publications Caio Max Rocha Lima has written about Proto-Oncogene Proteins c-bcl-2.
Connection Strength
0.059
-
Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest New Drugs. 2014 Oct; 32(5):937-45.
Score: 0.059